Bank of New York Mellon
PCVX icon

Bank of New York Mellon’s Vaxcyte PCVX Stock Holding History

Bank of New York Mellon’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.2M Buy
502,135
+27,609
+6% +$1.5M ﹤0.01% 1390
2026
Q1 		$27.6M Buy
474,526
+25,163
+6% +$1.37M 0.01% 1361
2025
Q4 		$20.7M Buy
449,363
+9,751
+2% +$436K ﹤0.01% 1518
2025
Q3 		$15.8M Sell
439,612
-10,082
-2% -$334K ﹤0.01% 1670
2025
Q2 		$14.6M Buy
449,694
+31,680
+8% +$1.04M ﹤0.01% 1687
2025
Q1 		$15.8M Sell
418,014
-3,924
-0.9% -$314K ﹤0.01% 1622
2024
Q4 		$34.5M Buy
421,938
+9,888
+2% +$982K 0.01% 1253
2024
Q3 		$47.1M Sell
412,050
-56,529
-12% -$5.09M 0.01% 1079
2024
Q2 		$35.4M Buy
468,579
+56,054
+14% +$3.82M 0.01% 1231
2024
Q1 		$28.2M Buy
412,525
+13,408
+3% +$928K 0.01% 1382
2023
Q4 		$25.1M Buy
399,117
+3,086
+0.8% +$160K 0.01% 1477
2023
Q3 		$20.2M Buy
396,031
+14,375
+4% +$709K ﹤0.01% 1537
2023
Q2 		$19.1M Buy
381,656
+80,610
+27% +$3.82M ﹤0.01% 1579
2023
Q1 		$11.3M Sell
301,046
-6,602
-2% -$280K ﹤0.01% 1872
2022
Q4 		$14.8M Buy
307,648
+128,078
+71% +$5.03M ﹤0.01% 1718
2022
Q3 		$4.31M Buy
179,570
+23,493
+15% +$596K ﹤0.01% 2365
2022
Q2 		$3.4M Buy
156,077
+3,713
+2% +$85.9K ﹤0.01% 2531
2022
Q1 		$3.68M Buy
152,364
+6,891
+5% +$151K ﹤0.01% 2585
2021
Q4 		$3.46M Buy
145,473
+7,875
+6% +$183K ﹤0.01% 2661
2021
Q3 		$3.49M Buy
137,598
+19,092
+16% +$463K ﹤0.01% 2680
2021
Q2 		$2.67M Buy
118,506
+33,669
+40% +$689K ﹤0.01% 2820
2021
Q1 		$1.68M Buy
84,837
+18,897
+29% +$476K ﹤0.01% 3029
2020
Q4 		$1.75M Buy
65,940
+12,925
+24% +$481K ﹤0.01% 2922
2020
Q3 		$2.62M Buy
+53,015
New +$2.11M ﹤0.01% 2521

Other funds holding PCVX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

Bank of New York Mellon's PCVX Position: Q2 2026 in Review

Bank of New York Mellon increased its Vaxcyte (PCVX) stake by 5.8% in Q2 2026, buying an estimated $1.5M and bringing the position to 502,135 shares worth $29.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1390.

Bank of New York Mellon first reported a position in PCVX in Q3 2020 and has held it in 24 quarters since. The position peaked at $47.1M in Q3 2024. 122 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Bank of New York Mellon held 502,135 shares of Vaxcyte worth $29.2M as of Q2 2026.
  • Bank of New York Mellon bought 27,609 Vaxcyte shares in Q2 2026, an estimated $1.5M.
  • Vaxcyte made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #1390 holding.
  • Bank of New York Mellon first reported a position in Vaxcyte in Q3 2020 and has held it in 24 quarters since.
  • Bank of New York Mellon's Vaxcyte position peaked at $47.1M in Q3 2024.
  • 122 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.